Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Pregnancy Complications

ClinicalTrials.gov lists 7,505 trials for Pregnancy Complications or a narrower condition beneath it. NICHD Neonatal Research Network has the most among industry and government lead sponsors, with 44.

MeSH D011248 Urogenital Diseases C12
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 191 Phase 1/2 Phase 1/2 80 Phase 2 Phase 2 270 Phase 2/3 Phase 2/3 112 Phase 3 Phase 3 396 Phase 4 Phase 4 448 Not applicable Not applicable 3,454 Observational Observational 2,550 Phase 1 Phase 1 191 Phase 1/2 Phase 1/2 80 Phase 2 Phase 2 270 Phase 2/3 Phase 2/3 112 Phase 3 Phase 3 396 Phase 4 Phase 4 448 Not applicable Not applicable 3,454 Observational Observational 2,550

Trials per phase (log scale)

1 more section with rows

409 of the 7,505 trials are tagged with Pregnancy Complications itself; the rest are tagged with a narrower condition beneath it.

Get the Pregnancy Complications report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Pregnancy Complications trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 10 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 516

1990: 3 trials (Observational 2, Not applicable 1) 1991: 2 trials (Phase 3 1, Phase 2/3 1) 1992: 3 trials (Observational 1, Not applicable 1, Phase 3 1) 1993: 8 trials (Observational 3, Phase 3 4, Phase 2 1) 1994: 3 trials (Observational 2, Phase 2/3 1) 1995: 6 trials (Observational 3, Not applicable 2, Phase 3 1) 1996: 8 trials (Observational 2, Not applicable 2, Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 1) 1997: 10 trials (Observational 5, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 1 1) 1998: 12 trials (Observational 4, Not applicable 1, Phase 3 3, Phase 2 2, Phase 1 2) 1999: 18 trials (Observational 8, Not applicable 3, Phase 3 3, Phase 2 4) 2000: 27 trials (Observational 9, Not applicable 6, Phase 4 2, Phase 3 5, Phase 2 2, Phase 1/2 3) 2001: 29 trials (Observational 3, Not applicable 11, Phase 4 2, Phase 3 4, Phase 2/3 2, Phase 2 1, Phase 1/2 3, Phase 1 3) 2002: 45 trials (Observational 8, Not applicable 17, Phase 4 5, Phase 3 7, Phase 2 3, Phase 1/2 3, Phase 1 2) 2003: 59 trials (Observational 16, Not applicable 17, Phase 4 5, Phase 3 13, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 2) 2004: 74 trials (Observational 15, Not applicable 29, Phase 4 9, Phase 3 10, Phase 2/3 1, Phase 2 9, Phase 1/2 1) 2005: 97 trials (Observational 28, Not applicable 28, Phase 4 7, Phase 3 12, Phase 2/3 3, Phase 2 12, Phase 1/2 2, Phase 1 5) 2006: 129 trials (Observational 37, Not applicable 45, Phase 4 11, Phase 3 15, Phase 2 15, Phase 1/2 1, Phase 1 5) 2007: 119 trials (Observational 44, Not applicable 40, Phase 4 10, Phase 3 11, Phase 2 8, Phase 1/2 3, Phase 1 3) 2008: 142 trials (Observational 48, Not applicable 47, Phase 4 14, Phase 3 12, Phase 2/3 7, Phase 2 9, Phase 1/2 2, Phase 1 3) 2009: 145 trials (Observational 58, Not applicable 45, Phase 4 9, Phase 3 11, Phase 2/3 8, Phase 2 4, Phase 1/2 2, Phase 1 8) 2010: 152 trials (Observational 58, Not applicable 59, Phase 4 9, Phase 3 9, Phase 2/3 1, Phase 2 10, Phase 1/2 4, Phase 1 2) 2011: 205 trials (Observational 61, Not applicable 86, Phase 4 21, Phase 3 17, Phase 2/3 4, Phase 2 5, Phase 1/2 3, Phase 1 8) 2012: 221 trials (Observational 71, Not applicable 89, Phase 4 19, Phase 3 17, Phase 2/3 3, Phase 2 14, Phase 1/2 4, Phase 1 4) 2013: 243 trials (Observational 93, Not applicable 92, Phase 4 15, Phase 3 16, Phase 2/3 5, Phase 2 11, Phase 1/2 4, Phase 1 7) 2014: 288 trials (Observational 100, Not applicable 126, Phase 4 23, Phase 3 14, Phase 2/3 6, Phase 2 12, Phase 1/2 3, Phase 1 4) 2015: 320 trials (Observational 114, Not applicable 127, Phase 4 22, Phase 3 22, Phase 2/3 10, Phase 2 12, Phase 1/2 4, Phase 1 9) 2016: 360 trials (Observational 134, Not applicable 146, Phase 4 31, Phase 3 23, Phase 2/3 8, Phase 2 13, Phase 1 5) 2017: 386 trials (Observational 136, Not applicable 175, Phase 4 25, Phase 3 21, Phase 2/3 13, Phase 2 7, Phase 1/2 2, Phase 1 7) 2018: 468 trials (Observational 150, Not applicable 235, Phase 4 29, Phase 3 23, Phase 2/3 5, Phase 2 14, Phase 1/2 4, Phase 1 8) 2019: 481 trials (Observational 182, Not applicable 232, Phase 4 21, Phase 3 19, Phase 2/3 6, Phase 2 11, Phase 1/2 3, Phase 1 7) 2020: 477 trials (Observational 188, Not applicable 228, Phase 4 22, Phase 3 14, Phase 2/3 5, Phase 2 9, Phase 1/2 2, Phase 1 9) 2021: 484 trials (Observational 173, Not applicable 252, Phase 4 24, Phase 3 13, Phase 2/3 1, Phase 2 10, Phase 1/2 3, Phase 1 8) 2022: 494 trials (Observational 175, Not applicable 257, Phase 4 23, Phase 3 12, Phase 2/3 2, Phase 2 14, Phase 1/2 3, Phase 1 8) 2023: 497 trials (Observational 162, Not applicable 266, Phase 4 23, Phase 3 11, Phase 2/3 5, Phase 2 11, Phase 1/2 3, Phase 1 16) 2024: 516 trials (Observational 162, Not applicable 292, Phase 4 16, Phase 3 13, Phase 2/3 4, Phase 2 13, Phase 1/2 4, Phase 1 12) 2025: 499 trials (Observational 156, Not applicable 268, Phase 4 28, Phase 3 12, Phase 2/3 4, Phase 2 12, Phase 1/2 2, Phase 1 17)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 410
2025 499
2024 516
2023 497
2022 494
2021 484
2020 477
2019 481
2018 468
2017 386

Forecast of the full-year count, planned starts included, not rows of this table: about 480 trials starting in 2026 and about 490 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 604 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 4,393 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Pregnancy Complications trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 191
Phase 1/2 80
Phase 2 270
Phase 2/3 112
Phase 3 396
Phase 4 448
Not applicable 3,454
Observational 2,550
Expanded access 4

How many Pregnancy Complications trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 400
Recruiting 836
Enrolling by invitation 61
Active, not recruiting 237
Completed 3,938

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Pregnancy Complications trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
NICHD Neonatal Research Network 44

Which drugs are being tested for Pregnancy Complications? (1)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
MisoprostoL 119

Interventions as named in the registry (14)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
IM Oxytocin 130
EC Aspirin 67
acid tranexamic 56
1% Metformin 56
carbetocin 100 µg 54

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Pregnancy Complications trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Stillbirth/neonatal death 5,079 1
Patent Ductus Aretriosus 631 1
Congenital anomaly 597 3
Death 491 22
Neonatal death up to 28 days 353 1

Which publications cover Pregnancy Complications? (3,123)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Sub-conditions in MeSH (25)

MeSH descendants one level down with at least one trial, most trials first.

+15 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages